NO996270L - Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor - Google Patents

Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor

Info

Publication number
NO996270L
NO996270L NO996270A NO996270A NO996270L NO 996270 L NO996270 L NO 996270L NO 996270 A NO996270 A NO 996270A NO 996270 A NO996270 A NO 996270A NO 996270 L NO996270 L NO 996270L
Authority
NO
Norway
Prior art keywords
glucosidase inhibitor
thiazolidinedione
alfa
diabetes
treatment
Prior art date
Application number
NO996270A
Other languages
English (en)
Other versions
NO996270D0 (no
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO996270D0 publication Critical patent/NO996270D0/no
Publication of NO996270L publication Critical patent/NO996270L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En fremgangsmåte for behandlingen av diabetes mellitus og tilstander som er assosiert med diabetes mellitus i et pattedyr, der fremgangsmåten innbefatter administrering av en effektiv ikke-toksisk og farmasøytiske godkjent mengde av en insulinsensitiverer og en antihyperglykemisk alfa-glukosidaseinhibitoragens til et pattedyr med behov derav.
NO996270A 1997-06-18 1999-12-17 Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor NO996270L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003691 WO1998057635A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor

Publications (2)

Publication Number Publication Date
NO996270D0 NO996270D0 (no) 1999-12-17
NO996270L true NO996270L (no) 1999-12-17

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996270A NO996270L (no) 1997-06-18 1999-12-17 Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor

Country Status (24)

Country Link
EP (1) EP0975343A1 (no)
JP (1) JP2001523271A (no)
KR (1) KR20010013845A (no)
CN (1) CN1274282A (no)
AP (1) AP9901720A0 (no)
AR (2) AR014881A1 (no)
AU (1) AU8799998A (no)
BG (1) BG103966A (no)
BR (1) BR9810186A (no)
CA (1) CA2294134A1 (no)
CO (1) CO4940453A1 (no)
DZ (1) DZ2519A1 (no)
EA (1) EA200000040A1 (no)
IL (1) IL133138A0 (no)
MA (1) MA26510A1 (no)
NO (1) NO996270L (no)
NZ (1) NZ501345A (no)
OA (1) OA11631A (no)
PE (1) PE89199A1 (no)
PL (1) PL337577A1 (no)
SK (1) SK179499A3 (no)
TR (1) TR199903072T2 (no)
UY (1) UY25051A1 (no)
WO (1) WO1998057635A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1173434B1 (en) 1999-04-23 2003-08-20 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
EP1392326B1 (en) 2001-04-04 2009-09-09 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
CN101121004B (zh) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 含有胰岛素增敏剂和米格列醇的药物组合物
CN101584688B (zh) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物
CN101584705B (zh) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003724A1 (en) * 1991-08-26 1993-03-04 The Upjohn Company Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
KR20010013845A (ko) 2001-02-26
IL133138A0 (en) 2001-03-19
SK179499A3 (en) 2000-11-07
NO996270D0 (no) 1999-12-17
BR9810186A (pt) 2000-08-08
AR014881A1 (es) 2001-04-11
MA26510A1 (fr) 2004-12-20
EP0975343A1 (en) 2000-02-02
NZ501345A (en) 2001-10-26
OA11631A (en) 2004-11-22
AU8799998A (en) 1999-01-04
CN1274282A (zh) 2000-11-22
DZ2519A1 (fr) 2003-02-01
EA200000040A1 (ru) 2000-08-28
PL337577A1 (en) 2000-08-28
BG103966A (bg) 2000-07-31
JP2001523271A (ja) 2001-11-20
AR013352A1 (es) 2000-12-27
UY25051A1 (es) 2000-09-29
WO1998057635A1 (en) 1998-12-23
CA2294134A1 (en) 1998-12-23
PE89199A1 (es) 1999-10-23
AP9901720A0 (en) 1999-12-31
TR199903072T2 (xx) 2000-07-21
CO4940453A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
NO20090846L (no) Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
UY25713A1 (es) Método para tratar diabetes empleando un inhibidor ap2 y combinación.
NO20083276L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
NO996270L (no) Behandling av diabetes med tiazolidindion og &lt;alfa&gt;- glukosidaseinhibitor
NO20000230L (no) Behandling av diabetes med tiazolidindion, insulin sekretagogue og &lt;alfa&gt;glukosidaseinhibitor
EA200000042A1 (ru) Способ лечения диабета росиглитазоном и инсулином
TR200101336T2 (tr) Bir-beta-agonisti ile başka bir antidiyabetik madde içeren kombinasyonlar
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
ECSP982592A (es) Nuevo metodo de tratamiento v
CO5150158A1 (es) Tratamiento antidiabetico novedoso
TR200000957T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı
HUP0002569A2 (hu) Diabetes kezelésére alkalmas dioxo-tiazolidint és alfa-glükozidáz inhibitort tartalmazó gyógyszerkészítmények
ECSP982591A (es) Nuevo metodo de tratamiento iv
ECSP982542A (es) Nuevo metodo de tratamiento iii
TR200000958T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı.
ECSP982593A (es) Nuevo metodo de tratamiento vi
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP993146A (es) Metodo de tratameinto para la diabetes empleando un inhibidor ap2 y su combinacion
HUP0002668A2 (hu) Diabetes kezelésére dioxo-tiazolidinnel és metforminnal

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application